Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis

• Published in: Journal of the American Heart Association Vol. 13; no. 16; p. e034815
• Main Authors: Oliva, Angelo, Ioppolo, Anna Maria, Chiarito, Mauro, Cremonesi, Alberto, Azzano, Alessia, Miccichè, Eligio, Mangiameli, Andrea, Ariano, Francesco, Ferrante, Giuseppe, Reimers, Bernhard, Garot, Philippe, Amabile, Nicolas, Mehran, Roxana, Condorelli, Gianluigi, Stefanini, Giulio, Cao, Davide
• Format: Journal Article
• Language: English
• Published: England Wiley 20-08-2024
• Subjects: Administration, Oral; Anticoagulants - administration & dosage; Anticoagulants - adverse effects; Anticoagulants - therapeutic use; Atrial Appendage - surgery; atrial fibrillation; Atrial Fibrillation - complications; Atrial Fibrillation - drug therapy; bleeding; Cardiac Catheterization - adverse effects; Cardiac Catheterization - methods; Hemorrhage - chemically induced; Humans; Left Atrial Appendage Closure; Network Meta-Analysis; oral anticoagulation; Risk Factors; stroke; Stroke - etiology; Stroke - prevention & control; Treatment Outcome; atrial fibrillation; bleeding; left atrial appendage closure; oral anticoagulation; stroke
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.124.034815

Percutaneous left atrial appendage closure (LAAC) has been suggested as an alternative to long-term oral anticoagulation for nonvalvular atrial fibrillation, but comparative data remain scarce. We aimed to assess ischemic and bleeding outcomes of LAAC compared with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) for the prevention of cardioembolic events in patients with atrial fibrillation.
Embase and MEDLINE were searched for randomized trials comparing LAAC, VKAs, and DOACs. The primary efficacy end point was any stroke or systemic embolism. Treatment effects were calculated from a network meta-analysis and ranked according to the surface under the cumulative ranking curve. Seven trials and 73 199 patients were included. The risk of the primary end point was not statistically different between LAAC versus VKAs (odds ratio [OR], 0.92 [95% CI, 0.62-1.50]) and LAAC versus DOACs (OR, 1.11 [95% CI, 0.71-1.73]). LAAC and DOACs resulted in similar risk of major or minor (OR, 0.93 [95% CI, 0.61-1.42]) and major bleeding (OR, 0.92 [95% CI, 0.58-1.46]); however, after exclusion of procedural bleeding, bleeding risk was significantly lower in those undergoing LAAC. Both LAAC and DOACs reduced the risk of all-cause death  compared with VKAs (LAAC versus VKAs: OR, 0.70 [95% CI, 0.53-0.91]; DOACs versus VKAs: OR, 0.90 [95% CI, 0.85-0.95], respectively). DOACs ranked as the best treatment for stroke or systemic embolism prevention (66.9%) and LAAC for reducing major bleeding (63.9%) and death (96.4%).
As a nonpharmacological alternative to oral anticoagulation for atrial fibrillation, LAAC showed similar efficacy and safety compared with VKAs or DOACs. Prospective confirmation from larger studies is warranted.